CRL-2407 NK-92 人惡性非霍奇金**瘤患者的自然殺傷細胞
ATCC® Number: CRL-2407? Price: $289.00
Designations: NK-92
Depositors: ZelleRx Corporation
Biosafety Level: 1 [Human ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension, multicell aggregates
Organism: Homo sapiens (human)
Morphology: lymphoblast
Source: Disease: malignant non-Hodgkin's lymphoma
Cell Type: natural killer cell; NK cell;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host (technology from amaxa)
Antigen Expression: CD2 +, CD7 +, CD11a +, CD28 + , CD45 +, CD54 +, CD56 +, CD1 -, CD3 -, CD4 -, CD5 -, CD8 -, CD10 -, CD14 -, CD16 -, CD19 -, CD20 -, CD23 -, CD34 -, HLA-DR -
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 9,12
D16S539: 11,12
D5S818: 12,13
D7S820: 10,11
THO1: 6,9.3
TPOX: 8
vWA: 18
Age: 50 years
Gender: male
Ethnicity: Caucasian, White
Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. [38894]
The cell line is dependent on the presence of recombinant Il-2 and a dose as low as 10 U/ml is sufficient to maintain proliferation; cells will die within 72 hours in the absence of IL-2. [38894]
The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. [38894]
NK-92 cells (after irradiation to prevent proliferation) can be used effectively for immunological ex vivo purging of leukemia from blood without compromising hematopoietic cell function. [38896]
NK-92 cells have the following characteristics: surfacemarker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4,CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. [38894]
Propagation: ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100-200 U/ml recombinant IL-2; adjust to a final concentration of 12.5% horse serum and 12.5% fetal bovine serum.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Growth Conditions: Successful growth of this cell line is very dependent upon the quality of IL-2 used in the growth medium. ATCC recommends using the highest quality IL-2 available.
Subculturing: Protocol: Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 2 to 3 X 10(5) viable cells/ml. Pipet the cells up and down on the back of the flask every 2-3 days to produce a single cell suspension.
NK-92 cells are extremely sensitive to overgrowth and media exhaustion.
Medium Renewal: Replace with fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: 50% FBS; 40% complete growth medium ; 10% DMSO.
Storage temperature: liquid nitrogen vapor phase
Related Products: recommended serum:ATCC 30-2020
recommended serum:ATCC 30-2040
derivative:ATCC CRL-2408
derivative:ATCC CRL-2409
References: 38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
38896: Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301
38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
39852: Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869
39854: Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151
39855: Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753
39857: Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501
39861: Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023
40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052
